- Home
- SNTI vs MCVT Comparison
SNTI vs MCVT Comparison
Compare SNTI & MCVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- MCVT
- Stock Information
- Founded
- SNTI 2016
- MCVT 2007
- Country
- SNTI United States
- MCVT United States
- Employees
- SNTI N/A
- MCVT N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- MCVT Finance Companies
- Sector
- SNTI Health Care
- MCVT Finance
- Exchange
- SNTI Nasdaq
- MCVT Nasdaq
- Market Cap
- SNTI 14.1M
- MCVT 14.7M
- IPO Year
- SNTI N/A
- MCVT N/A
- Fundamental
- Price
- SNTI $2.24
- MCVT $2.13
- Analyst Decision
- SNTI
- MCVT
- Analyst Count
- SNTI 0
- MCVT 0
- Target Price
- SNTI N/A
- MCVT N/A
- AVG Volume (30 Days)
- SNTI 19.4K
- MCVT 132.3K
- Earning Date
- SNTI 11-11-2024
- MCVT 11-15-2024
- Dividend Yield
- SNTI N/A
- MCVT N/A
- EPS Growth
- SNTI N/A
- MCVT N/A
- EPS
- SNTI N/A
- MCVT 0.04
- Revenue
- SNTI $338,000.00
- MCVT $3,248,401.00
- Revenue This Year
- SNTI $254.47
- MCVT N/A
- Revenue Next Year
- SNTI $169.66
- MCVT N/A
- P/E Ratio
- SNTI N/A
- MCVT $59.35
- Revenue Growth
- SNTI N/A
- MCVT N/A
- 52 Week Low
- SNTI $1.52
- MCVT $2.10
- 52 Week High
- SNTI $8.48
- MCVT $3.88
- Technical
- Relative Strength Index (RSI)
- SNTI 37.17
- MCVT 36.04
- Support Level
- SNTI $2.05
- MCVT $2.23
- Resistance Level
- SNTI $2.46
- MCVT $2.47
- Average True Range (ATR)
- SNTI 0.25
- MCVT 0.30
- MACD
- SNTI -0.09
- MCVT -0.08
- Stochastic Oscillator
- SNTI 15.32
- MCVT 0.00
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About MCVT Mill City Ventures III Ltd.
Mill City Ventures III Ltd is a non-bank lender and specialty finance company. The company is engaged in the business of providing short-term specialty finance solutions primarily to private businesses, micro-and small-cap public companies, and high-net-worth individuals. The principal specialty finance solutions that they provide are high-interest short-term lending arrangements. Typically, these lending arrangements involve obtaining collateral as security for the borrower's repayment of funds, or personal guarantees from the principals or affiliates of the borrower.